| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IT3-H82W9 | Human | Biotinylated Human Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein, His,Avitag™&Tag Free |  |
|
|
| IT3-H52E3 | Human | Human Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein, His Tag&Tag Free (MALS verified) |  |
|
|
Immobilized Human Fibronectin at 2 μg/mL (100 μL/well) can bind Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) with a linear range of 0.01-0.3 μg/mL (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Peptide-based PET radiotracer (Stanford University) | Phase 2 Clinical | Stanford University | Neoplasms | Details | |
| Pagantangentide | Phase 1 Clinical | Nanjing Anji Biological Technology Co Ltd, Jiangsu Aotexin Biomedical Technology Co Ltd, China Pharmaceutical University | Arthritis, Rheumatoid; Rheumatic Diseases | Details | |
| Antiangiotide | HM-3; IIM-3 | Phase 1 Clinical | Inner Mongolia Tianqi Pharmaceutical Group Co Ltd, China Pharmaceutical University | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Abituzumab | DI-17E6; EMD-525797 | Phase 2 Clinical | Merck Serono | Bone metastases; Solid tumours; Scleroderma, Systemic; Ovarian Diseases; Prostatic Neoplasms; Colorectal Neoplasms | Details |
| IDL-2965 | IDL-2965 | Phase 2 Clinical | Indalo Therapeutics | Non-alcoholic Fatty Liver Disease; Idiopathic Pulmonary Fibrosis | Details |
| SF-0166 | SF-0166 | Phase 2 Clinical | Scifluor Life Sciences | Diabetic macular oedema; Macular Degeneration | Details |
| AS-101 | WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101; PRX-0001/AS101 | Phase 2 Clinical | Biomas | Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Macular Degeneration; Condylomata Acuminata; Dermatitis, Atopic | Details |
| ProAgio | Phase 1 Clinical | National Cancer Institute | Solid tumours; Pancreatic Neoplasms | Details | |
| Risuteganib | ALG-1001 | Phase 2 Clinical | Allegro Ophthalmics | Retinal Diseases; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration | Details |
| 68Ga-NOTA-BBN-RGD | 68Ga-NOTA-BBN-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms; Prostatic Neoplasms | Details |
| 68Ga-NOTA-3PTATE-RGD | 68Ga-NOTA-3PTATE-RGD; 68Ga-NOTA-3P-TATE-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Lung Neoplasms | Details |
| 99mTc-3PRGD2 | 99mTc-3PRGD2 | Phase 3 Clinical | Peking University | Lymphatic Metastasis; Lung Neoplasms | Details |
| [68Ga]-FF58 | Phase 1 Clinical | Stomach Neoplasms; Esophageal Neoplasms; Glioblastoma; Brain Neoplasms; Carcinoma, Pancreatic Ductal | Details | ||
| Alfatide[18F] | Phase 3 Clinical | Taizhou Kairui Pharmaceutical Technology Co Ltd, Jiangsu Smk Pharmaceutical Co Ltd | Neoplasms; Contrast agents | Details | |
| BGC-0222 | BGC0222; BGC-0222 | Phase 1 Clinical | Gaorui Yaoye (Beijing) Technologies Co Ltd, Brightgene Bio-Medical Technology Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z
